Brain Health

Advanced practice provider (APP) care models allow for health systems to better individualize care for patients, effectively meeting their needs.

BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.

Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.

About 59.2% of patients with tardive dyskinesia (TD) who completed the 48-week trial achieved remission.

Patients with a disorder from this family of neurodevelopmental conditions face a lack of approved treatment options, making radiprodil poised to transform the treatment paradigm.

Long-acting injectables offer a promising approach to schizophrenia treatment, but their effective use requires careful management and patient education.

Currently, EN001 is undergoing evaluation in a phase 1b trial.

Michael McGuire, PharmD, highlights the importance of early intervention in hospital settings, leveraging manufacturer programs, and navigating complex dosing regimens.

The move is expected to expand clozapine access for patients with schizophrenia.

LAIs offer a variety of benefits, from improved medication adherence and relapse prevention to enhanced quality of life for individuals with schizophrenia.

The data were released in the CDC’s Morbidity and Mortality Weekly Report.

Research has demonstrated a reduction in hospitalization risk associated with the use of LAIs, but some barriers can prevent the wider adoption of this approach.

The designation is supported by pooled data from 4 clinical trials.

Pharmacists can support patients with treatment education, monitoring, and adherence, helping to overcome challenges posed by cognitive decline.

Amlenetug could provide a treatment option for patients with multiple system atrophy, a progressive and rare condition that causes damage to the brain’s nerve cells.

Pharmacists can help patients and their caregivers manage seizures, assess seizure control, and recommend appropriate treatments such as phenobarbital or rescue medications.

Risdiplam is the only approved non-invasive disease-modifying SMA treatment.

Supplements, such as Prevagen, as well as lifestyle and diet modifications can provide additional support to patients with Alzheimer disease.

In the phase 3 CONNEX clinical trial program, iclepertin did not meet its primary and secondary end points.

There were no substantial differences for the mindfulness with substance use or anxiety outcomes compared with the recovery control group.

Pregnant individuals with multiple sclerosis (MS) are more likely to experience mental illness both during their pregnancy and in the first years after giving birth.

Prescription stimulant dispensing was greatly impacted by the COVID-19 pandemic and drug shortages.

Health care professionals, particularly pharmacists, can recommend that patients take over-the-counter supplements, such as melatonin, to facilitate REM sleep.

Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.

Additionally, the authors observe that childhood-onset epilepsy is associated with an earlier age at the onset of amyloidosis.

Administered every 4 weeks, the approval could serve as a breakthrough for easier and more effective care for patients with early Alzheimer disease.

Based on the updated label, new pharmacodynamic data have been added for a better understanding of the drug for individuals with attention-deficit/hyperactivity disorder (ADHD).

Pharmacists bridge communication gaps and enhance shared decision-making.

Despite these findings, navacaprant was generally well-tolerated and safe in patients with major depressive disorder.

Memantine/donepezil and everolimus are used to treat dementia of the Alzheimer type and tuberous sclerosis complex-associated subependymal giant cell astrocytoma, respectively.